Improving and increasing diversity, equity, and inclusion in the digitized clinical trial design process
Today’s clinical trials fail to represent the diversity of the general population or those with specific diseases. However, digital approaches offer a new suite of opportunities to improve diversity, equity, and inclusion in clinical trials. This project aims to ensure that the promise of easier access, broader inclusion, and more generalizable findings is finally realized.
Ensure that the digitization of clinical trials results in a more accessible and inclusive clinical research enterprise that produces more generalizable findings, and extends the benefits of new medical products to all members of the population.
Develop best practices, pragmatic resources, and educational materials that will support life science companies in designing clinical trials that successfully engage, enroll and retain underrepresented populations.
The DiMe Diversity, Equity, and Inclusion in Digitized Clinical Trials project will develop the best practices necessary to harness the promise of digital transformation of clinical trials to benefit all individuals, not just the over-represented few.
Diversity of data is a critical factor for advancing healthcare; this will only be achieved through equitable practices that ensure more inclusivity of underrepresented and underserved populations, in all steps of the clinical trials process, including recruitment, conduct, and data analysis.
We are proud to bring together life science companies; diversity, equity, and inclusion experts; and other leaders from the health-tech continuum together in this pre-competitive environment to advance the field for all.
DiMe and our project partners are committed to clinical quality work on a tech timeline.
Action-oriented resources will be launched in early 2023.